An observational study in HIV Infections, sponsored by Hospital de Clinicas de Porto Alegre. Completed at 1 site in Brazil. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-08-11.
Sponsored by Hospital de Clinicas de Porto Alegre · Observational
The purpose of this study is to compare oxidative stress markers and the immunologic characteristics of HIV-infected and non-HIV subjects during a bout of moderate aerobic exercise followed by resistance exercises
4,340 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
This study's enrollment of 28 is below the median of 200 across 731 observational studies indexed under HIV Infections.
Browse HIV Infections studies →Hospital de Clinicas de Porto Alegre is the lead sponsor of 456 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The participants of the HIV group were recruited at the outpatient HIV/AIDS care unit of the Hospital de Clínicas de Porto Alegre (HCPA), whereas the control group (non-HIV) was formed by volunteers of the city of Porto Alegre, Rio Grande do Sul, Brazil
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HIV infected persons
Non HIV-infected persons
Total Glutathione
The total glutathione content in erythrocyte concentrate at three moments: baseline, aerobic and resistance exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
Catalase Activity
Antioxidant activity of the catalase enzyme at three moments: baseline, aerobic and exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
Glutathione S-transferase (GST)
Antioxidant activity of the Glutathione S-transferase enzyme at three moments: baseline, aerobic and resistance exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
Lipid Peroxidation
Thiobarbituric acid-reactive substances (TBARS) assay was used as an index of lipid peroxidation in erythrocytes, at three moments: baseline, aerobic and resistance exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
T CD4
T CD4 lymphocytes counts at three moments: baseline, aerobic and resistance exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
Neutrophil Count
Neutrophil count at three moments: baseline, aerobic and resistance exercise.
Time frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).
Peak Oxygen Uptake
Is the maximum capacity of an individual's body to transport and utilize oxygen during incremental exercise.
Time frame: 1 time, before the exercise protocol
| Milestone | HIV Group | Control Group |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
Antioxidant activity of the catalase enzyme at three moments: baseline, aerobic and exercise.
| units of catalase /mg protein | HIV Group | Control Group |
|---|---|---|
| Baseline | 0.578 (0.049 to 1.338) | 0.967 (0.312 to 2.322) |
| Aerobic | 1.03 (0.316 to 2.598) | 0.855 (0.087 to 1.688) |
| Resistance | 0.566 (0.317 to 3.510) | 1.009 (0.333 to 2.096) |
The total glutathione content in erythrocyte concentrate at three moments: baseline, aerobic and resistance exercise.
| nmoles glutathione/ ml of sample | HIV Group | Control Group |
|---|---|---|
| Baseline | 1,964 (319 to 2,577) | 3,490 (597 to 7,596) |
| Aerobic | 1,865 (780 to 5,006) | 3,995 (2,308 to 6,068) |
| Resistance | 1,767 (516 to 2,420) | 3,206 (2,456 to 7,202) |
Antioxidant activity of the Glutathione S-transferase enzyme at three moments: baseline, aerobic and resistance exercise.
| micromol of GST/min/mg of protein | HIV Group | Control Group |
|---|---|---|
| Baseline | 0.34 (0.18 to 0.58) | 0.5 (0.42 to 0.56) |
| Aerobic | 0.34 (0.09 to 0.42) | 0.36 (0.34 to 0.51) |
| Resistance | 0.45 (0.31 to 0.63) | 0.46 (0.43 to 0.65) |
Thiobarbituric acid-reactive substances (TBARS) assay was used as an index of lipid peroxidation in erythrocytes, at three moments: baseline, aerobic and resistance exercise.
| picomol of TBARS/mg protein | HIV Group | Control Group |
|---|---|---|
| Baseline | 2.356 (1.27 to 3.12) | 2.888 (1.118 to 5.002) |
| Aerobic | 2.328 (0.909 to 2.922) | 4.164 (2.763 to 6.790) |
| Resistance | 2.348 (0.917 to 3.794) | 3.205 (1.753 to 6.840) |
T CD4 lymphocytes counts at three moments: baseline, aerobic and resistance exercise.
| Cell/ul of blood | HIV Group | Control Group |
|---|---|---|
| Baseline | 417 (116 to 1132) | 984 (594 to 2145) |
| Aerobic | 428 (70 to 811) | 968 (553 to 1387) |
| Resistance | 378 (70 to 981) | 974 (643 to 1411) |
Neutrophil count at three moments: baseline, aerobic and resistance exercise.
| Cell/ul of blood | HIV Group | Control Group |
|---|---|---|
| Baseline | 3,237 (1,901 to 4,207) | 3,212 (2,328 to 4,174) |
| Aerobic | 3,285 (1,610 to 5,476) | 3,476 (2,184 to 9,236) |
| Resistance | 3,511 (1,531 to 5,977) | 3,563 (2,422 to 9,214) |
Is the maximum capacity of an individual's body to transport and utilize oxygen during incremental exercise.
| ml/min | HIV Group | Control Group |
|---|---|---|
| Peak Oxygen Uptake | 1,673 ± 349 | 2,167 ± 597 |
| Age, Categorical(Participants) | HIV Group | Control Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0.0 |
| Between 18 and 65 years | 14 | 14 | 28.0 |
| >=65 years | 0 | 0 | 0.0 |
| Age Continuous(years) | HIV Group | Control Group | Total |
|---|---|---|---|
| Mean | 39.2 ± 8.7 | 36 ± 10.6 | 37.5 ± 9.5 |
| Sex: Female, Male(Participants) | HIV Group | Control Group | Total |
|---|---|---|---|
| Female | 7 | 7 | 14.0 |
| Male | 7 | 7 | 14.0 |
| Region of Enrollment(participants) | HIV Group | Control Group | Total |
|---|---|---|---|
| Brazil | 14 | 14 | 28.0 |
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Clinicas de Porto Alegre →